Azitra, Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Azitra, Inc. (NYSE American: AZTR) is a clinical-stage biopharmaceutical company focused on developing precision dermatology therapies using engineered proteins and live biotherapeutic products derived from the skin microbiome to treat skin diseases; its lead pipeline candidates include ATR-12, a genetically modified LEKTI-secreting auxotrophic strain of Staphylococcus epidermidis in Phase 1b for Netherton syndrome, a rare genetic skin disorder; ATR-04, an auxotrophic S. epidermidis strain in Phase 1/2 targeting papulopustular rash associated with EGFR inhibitor cancer therapies; and ATR-01, a recombinant human filaggrin protein for ichthyosis vulgaris. The company, founded in 2014 and headquartered at 21 Business Park Drive in Branford, Connecticut, leverages a proprietary Microbiome Dermatology Platform encompassing a library of approximately 1,500 bacterial strains, genetic engineering tools, and AI-driven screening to engineer commensal skin bacteria like S. epidermidis for topical delivery of therapeutic proteins addressing inflammatory, barrier-defective, and infectious skin conditions; it also pursues consumer skincare products for dry, inflamed, or sensitive skin through program areas including DoD-funded advanced microbiome applications against Staph aureus and biosensors for biohazards. Azitra maintains a strategic collaboration with Bayer under a 2019 joint development agreement to identify S. epidermidis strains for natural skincare targeting eczema-prone skin; recent developments include a $20 million share purchase agreement with Alumni Capital LP announced in April 2025 to fund clinical pipeline advancement with minimized dilution, followed by a $1.5 million private placement priced at a premium in November 2025 comprising 4.687 million shares and warrants, plus Q3 2025 progress with dosing in live biotherapeutic programs.
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Azitra, Inc. to Present at 2026 BIO International Convention
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Why Are Shares Of Azitra Rising?
Azitra Inc. (AZTR) Surges Over 44% After Hours— Here's Why It's Trending
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
Azitra, Inc. to Present at BIO Investment & Growth Summit
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Azitra (NYSEAMERICAN:AZTR) Trading Down 4.7% – Here’s Why